instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
Could you provide the median PFS of Intravenous Daratumumab (Dara IV)? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: Could you provide the median PFS of Intravenous Daratumumab (Dara IV)?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
I’d like to know the median PFS of Intravenous Daratumumab (Dara IV). | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: I’d like to know the median PFS of Intravenous Daratumumab (Dara IV).
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
Do you have information on the median PFS of Intravenous Daratumumab (Dara IV)? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: Do you have information on the median PFS of Intravenous Daratumumab (Dara IV)?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
What is the median progression-free survival (PFS) for Intravenous Daratumumab (Dara IV)? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: What is the median progression-free survival (PFS) for Intravenous Daratumumab (Dara IV)?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
Can you inform me about the median PFS for Intravenous Daratumumab (Dara IV)? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: Can you inform me about the median PFS for Intravenous Daratumumab (Dara IV)?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
I’m interested in the median PFS of Intravenous Daratumumab (Dara IV). | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: I’m interested in the median PFS of Intravenous Daratumumab (Dara IV).
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
Could you tell me the median PFS for Intravenous Daratumumab (Dara IV)? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: Could you tell me the median PFS for Intravenous Daratumumab (Dara IV)?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
What is the median PFS rate for Intravenous Daratumumab (Dara IV)? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: What is the median PFS rate for Intravenous Daratumumab (Dara IV)?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Intravenous Daratumumab (Dara IV) regimen? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Intravenous Daratumumab (Dara IV) regimen?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
What is the median PFS rate in patients who have undergone Intravenous Daratumumab (Dara IV) regimen? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: What is the median PFS rate in patients who have undergone Intravenous Daratumumab (Dara IV) regimen?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Intravenous Daratumumab (Dara IV) regimen? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Intravenous Daratumumab (Dara IV) regimen?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
What’s the median PFS rate for patients receiving Intravenous Daratumumab (Dara IV) regimen? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: What’s the median PFS rate for patients receiving Intravenous Daratumumab (Dara IV) regimen?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
Could you provide the median Progression-Free Survival rate for patients treated with Intravenous Daratumumab (Dara IV) regimen? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Intravenous Daratumumab (Dara IV) regimen?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
What is the median rate of Progression-Free Survival in patients who have been treated with Intravenous Daratumumab (Dara IV) regimen? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Intravenous Daratumumab (Dara IV) regimen?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
Can you inform me about the median PFS rate in patients that were treated with Intravenous Daratumumab (Dara IV) regimen? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Intravenous Daratumumab (Dara IV) regimen?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
What is the median PFS rate for patients that have undergone Intravenous Daratumumab (Dara IV) regimen? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: What is the median PFS rate for patients that have undergone Intravenous Daratumumab (Dara IV) regimen?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
Could you tell me the median Progression-Free Survival rate for patients who received Intravenous Daratumumab (Dara IV) regimen? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Intravenous Daratumumab (Dara IV) regimen?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
What’s the median rate of PFS in patients treated with Intravenous Daratumumab (Dara IV) regimen? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: What’s the median rate of PFS in patients treated with Intravenous Daratumumab (Dara IV) regimen?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
Can you share the median Progression-Free Survival rate in patients who have received Intravenous Daratumumab (Dara IV) regimen? | Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Intravenous Daratumumab (Dara IV) regimen?
### Response: Patients treated with the Intravenous Daratumumab (Dara IV) have a median Progression-Free Survival (PFS) rate of 6.1 months, with a 95% CI of (4.7, 8.3). |
Can you tell me the median PFS for Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: Can you tell me the median PFS for Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
What’s the median PFS associated with Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: What’s the median PFS associated with Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
Could you provide the median PFS of Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: Could you provide the median PFS of Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
I’d like to know the median PFS of Idecabtagene Vicleucel (Ide-Cel). | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: I’d like to know the median PFS of Idecabtagene Vicleucel (Ide-Cel).
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
Do you have information on the median PFS of Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: Do you have information on the median PFS of Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
What is the median progression-free survival (PFS) for Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: What is the median progression-free survival (PFS) for Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
Can you inform me about the median PFS for Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: Can you inform me about the median PFS for Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
I’m interested in the median PFS of Idecabtagene Vicleucel (Ide-Cel). | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: I’m interested in the median PFS of Idecabtagene Vicleucel (Ide-Cel).
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
Could you tell me the median PFS for Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: Could you tell me the median PFS for Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
What is the median PFS rate for Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: What is the median PFS rate for Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
What is the median PFS rate in patients who have undergone Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: What is the median PFS rate in patients who have undergone Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
What’s the median PFS rate for patients receiving Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: What’s the median PFS rate for patients receiving Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
Could you provide the median Progression-Free Survival rate for patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
What is the median rate of Progression-Free Survival in patients who have been treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
Can you inform me about the median PFS rate in patients that were treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
What is the median PFS rate for patients that have undergone Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: What is the median PFS rate for patients that have undergone Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
Could you tell me the median Progression-Free Survival rate for patients who received Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
What’s the median rate of PFS in patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: What’s the median rate of PFS in patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
Can you share the median Progression-Free Survival rate in patients who have received Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 8.8 months, with a 95% CI of (5.6, 11.6). |
Can you tell me the median PFS for 2.5 Mg / Kg Belantamab Mafodotin? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: Can you tell me the median PFS for 2.5 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
What’s the median PFS associated with 2.5 Mg / Kg Belantamab Mafodotin? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: What’s the median PFS associated with 2.5 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
Could you provide the median PFS of 2.5 Mg / Kg Belantamab Mafodotin? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: Could you provide the median PFS of 2.5 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
I’d like to know the median PFS of 2.5 Mg / Kg Belantamab Mafodotin. | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: I’d like to know the median PFS of 2.5 Mg / Kg Belantamab Mafodotin.
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
Do you have information on the median PFS of 2.5 Mg / Kg Belantamab Mafodotin? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: Do you have information on the median PFS of 2.5 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
What is the median progression-free survival (PFS) for 2.5 Mg / Kg Belantamab Mafodotin? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: What is the median progression-free survival (PFS) for 2.5 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
Can you inform me about the median PFS for 2.5 Mg / Kg Belantamab Mafodotin? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: Can you inform me about the median PFS for 2.5 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
I’m interested in the median PFS of 2.5 Mg / Kg Belantamab Mafodotin. | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: I’m interested in the median PFS of 2.5 Mg / Kg Belantamab Mafodotin.
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
Could you tell me the median PFS for 2.5 Mg / Kg Belantamab Mafodotin? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: Could you tell me the median PFS for 2.5 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
What is the median PFS rate for 2.5 Mg / Kg Belantamab Mafodotin? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: What is the median PFS rate for 2.5 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
What is the median Progression-Free Survival (PFS) rate in patients treated with 2.5 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with 2.5 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
What is the median PFS rate in patients who have undergone 2.5 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: What is the median PFS rate in patients who have undergone 2.5 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with 2.5 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with 2.5 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
What’s the median PFS rate for patients receiving 2.5 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: What’s the median PFS rate for patients receiving 2.5 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
Could you provide the median Progression-Free Survival rate for patients treated with 2.5 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with 2.5 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
What is the median rate of Progression-Free Survival in patients who have been treated with 2.5 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with 2.5 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
Can you inform me about the median PFS rate in patients that were treated with 2.5 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with 2.5 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
What is the median PFS rate for patients that have undergone 2.5 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: What is the median PFS rate for patients that have undergone 2.5 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
Could you tell me the median Progression-Free Survival rate for patients who received 2.5 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received 2.5 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
What’s the median rate of PFS in patients treated with 2.5 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: What’s the median rate of PFS in patients treated with 2.5 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
Can you share the median Progression-Free Survival rate in patients who have received 2.5 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received 2.5 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 2.5 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 2.9 months, with a 95% CI of (2.1, 3.7). |
Can you tell me the median PFS for 3.4 Mg / Kg Belantamab Mafodotin? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: Can you tell me the median PFS for 3.4 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
What’s the median PFS associated with 3.4 Mg / Kg Belantamab Mafodotin? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: What’s the median PFS associated with 3.4 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
Could you provide the median PFS of 3.4 Mg / Kg Belantamab Mafodotin? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: Could you provide the median PFS of 3.4 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
I’d like to know the median PFS of 3.4 Mg / Kg Belantamab Mafodotin. | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: I’d like to know the median PFS of 3.4 Mg / Kg Belantamab Mafodotin.
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
Do you have information on the median PFS of 3.4 Mg / Kg Belantamab Mafodotin? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: Do you have information on the median PFS of 3.4 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
What is the median progression-free survival (PFS) for 3.4 Mg / Kg Belantamab Mafodotin? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: What is the median progression-free survival (PFS) for 3.4 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
Can you inform me about the median PFS for 3.4 Mg / Kg Belantamab Mafodotin? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: Can you inform me about the median PFS for 3.4 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
I’m interested in the median PFS of 3.4 Mg / Kg Belantamab Mafodotin. | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: I’m interested in the median PFS of 3.4 Mg / Kg Belantamab Mafodotin.
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
Could you tell me the median PFS for 3.4 Mg / Kg Belantamab Mafodotin? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: Could you tell me the median PFS for 3.4 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
What is the median PFS rate for 3.4 Mg / Kg Belantamab Mafodotin? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: What is the median PFS rate for 3.4 Mg / Kg Belantamab Mafodotin?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
What is the median Progression-Free Survival (PFS) rate in patients treated with 3.4 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with 3.4 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
What is the median PFS rate in patients who have undergone 3.4 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: What is the median PFS rate in patients who have undergone 3.4 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with 3.4 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with 3.4 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
What’s the median PFS rate for patients receiving 3.4 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: What’s the median PFS rate for patients receiving 3.4 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
Could you provide the median Progression-Free Survival rate for patients treated with 3.4 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with 3.4 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
What is the median rate of Progression-Free Survival in patients who have been treated with 3.4 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with 3.4 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
Can you inform me about the median PFS rate in patients that were treated with 3.4 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with 3.4 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
What is the median PFS rate for patients that have undergone 3.4 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: What is the median PFS rate for patients that have undergone 3.4 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
Could you tell me the median Progression-Free Survival rate for patients who received 3.4 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received 3.4 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
What’s the median rate of PFS in patients treated with 3.4 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: What’s the median rate of PFS in patients treated with 3.4 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
Can you share the median Progression-Free Survival rate in patients who have received 3.4 Mg / Kg Belantamab Mafodotin regimen? | Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received 3.4 Mg / Kg Belantamab Mafodotin regimen?
### Response: Patients treated with the 3.4 Mg / Kg Belantamab Mafodotin have a median Progression-Free Survival (PFS) rate of 4.9 months, with a 95% CI of (2.3, 6.2). |
Can you tell me the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel)? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: Can you tell me the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel)?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
What’s the median PFS associated with Ciltacabtagene Autoleucel (Cilta-Cel)? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: What’s the median PFS associated with Ciltacabtagene Autoleucel (Cilta-Cel)?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
Could you provide the median PFS of Ciltacabtagene Autoleucel (Cilta-Cel)? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: Could you provide the median PFS of Ciltacabtagene Autoleucel (Cilta-Cel)?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
I’d like to know the median PFS of Ciltacabtagene Autoleucel (Cilta-Cel). | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: I’d like to know the median PFS of Ciltacabtagene Autoleucel (Cilta-Cel).
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
Do you have information on the median PFS of Ciltacabtagene Autoleucel (Cilta-Cel)? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: Do you have information on the median PFS of Ciltacabtagene Autoleucel (Cilta-Cel)?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
What is the median progression-free survival (PFS) for Ciltacabtagene Autoleucel (Cilta-Cel)? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: What is the median progression-free survival (PFS) for Ciltacabtagene Autoleucel (Cilta-Cel)?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
Can you inform me about the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel)? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: Can you inform me about the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel)?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
I’m interested in the median PFS of Ciltacabtagene Autoleucel (Cilta-Cel). | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: I’m interested in the median PFS of Ciltacabtagene Autoleucel (Cilta-Cel).
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
Could you tell me the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel)? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: Could you tell me the median PFS for Ciltacabtagene Autoleucel (Cilta-Cel)?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
What is the median PFS rate for Ciltacabtagene Autoleucel (Cilta-Cel)? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: What is the median PFS rate for Ciltacabtagene Autoleucel (Cilta-Cel)?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
What is the median PFS rate in patients who have undergone Ciltacabtagene Autoleucel (Cilta-Cel) regimen? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: What is the median PFS rate in patients who have undergone Ciltacabtagene Autoleucel (Cilta-Cel) regimen?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
What’s the median PFS rate for patients receiving Ciltacabtagene Autoleucel (Cilta-Cel) regimen? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: What’s the median PFS rate for patients receiving Ciltacabtagene Autoleucel (Cilta-Cel) regimen?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
Could you provide the median Progression-Free Survival rate for patients treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
What is the median rate of Progression-Free Survival in patients who have been treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
Can you inform me about the median PFS rate in patients that were treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Ciltacabtagene Autoleucel (Cilta-Cel) regimen?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
What is the median PFS rate for patients that have undergone Ciltacabtagene Autoleucel (Cilta-Cel) regimen? | Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). | ### Instruction: What is the median PFS rate for patients that have undergone Ciltacabtagene Autoleucel (Cilta-Cel) regimen?
### Response: Patients treated with the Ciltacabtagene Autoleucel (Cilta-Cel) have a median Progression-Free Survival (PFS) rate of NE months, with a 95% CI of (24.5, NE). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.